When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
KRYS - Krystal Bio gene therapy KR103 shows durable effect in rare skin blistering disorder
Krystal Biotech Inc.
In a final update on its Phase 1/2 clinical trial evaluating topical gene therapy bercolagene telserpavec (B-VEC) (formerly KB103) for the treatment of rare inherited skin disorder called dystrophic epidermolysis bullosa (DEB), Krystal Biotech (NASDAQ:KRYS) announces a 90% (n=9/10) wound closure rate following an initial administration.
More news on: Krystal Biotech, Inc., Healthcare stocks news,